Why the study?
Safety concerns, bleeding risk assessment, and bleeding management strategies require review in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants.
This review summarizes the safety profile, bleeding risk assessment, and management strategies for direct oral anticoagulants in patients with non-valvular atrial fibrillation.
Review discusses the problem of non-vitamin K antagonist oral anticoagulants safety in patients with non-valvular atrial fibrillation. Bleeding risk assessment while applying anticoagulant therapy, preventive methods for major bleeding (intracranial, gastro-intestinal) during this therapy as well as the strategy of treating patients with bleedings occurring on direct oral anticoagulants intake are discussed in this review. Special attention is paid to the choice of direct oral anticoagulant, the importance of specific antagonist of dabigatran – idarucizumab and indications for its clinical application.
No takes yet. Share an insight, caveat, or question.
Baranova et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: